Importantly, however, the data available demonstrate that PIK3CA activating mutations are neither required nor sufficient for a tumor to be sensitive to PI3K pathway inhibitors, and that a substantial proportion of cases with PIK3CA activating mutations may be de novo resistant to these agents. The gene discussed is PIK3CA; the disease is neoplasm.